PMID- 19646670
OWN - NLM
STAT- MEDLINE
DCOM- 20091022
LR  - 20151119
IS  - 1873-4332 (Electronic)
IS  - 1083-3188 (Linking)
VI  - 22
IP  - 4
DP  - 2009 Aug
TI  - Obstetrician-gynecologists and the HPV vaccine: practice patterns, beliefs, and 
      knowledge.
PG  - 239-46
LID - 10.1016/j.jpag.2008.09.002 [doi]
AB  - STUDY OBJECTIVE: Human papillomavirus (HPV), the most common sexually transmitted 
      infection in the United States, can be contracted by young girls shortly after 
      sexual debut. Human papillomavirus can lead to cervical and anogenital cancers 
      and genital warts. A vaccine has been developed to protect against precancerous 
      lesions. We examined obstetrician-gynecologists' practices, opinions, and 
      knowledge regarding this vaccine. DESIGN: A 37-item questionnaire was sent out by 
      the American College of Obstetricians and Gynecologists (ACOG) to its fellows and 
      junior fellows between May and November of 2007. PARTICIPANTS: Surveys went to 
      3896 fellows and junior fellows of ACOG. Of these surveys, 771 were Collaborative 
      Ambulatory Research Network (CARN) members who have volunteered to receive 
      several surveys per year. The remaining 3125 questionnaires were sent to all 
      fellows and junior fellows in ACOG's District V (Ohio, Kentucky, Indiana, 
      Michigan and Ontario, Canada). Response rates were 51.0% and 30.7% for CARN and 
      District V, respectively. RESULTS: Of those who administer vaccines, most offer 
      the HPV vaccine. Most know this vaccine protects against 4 HPV types. Fewer knew 
      the percentages of cervical cancers and genital warts prevented. Over 20% knew 
      all 3 answers. Only a minority answered all incorrectly. Approximately 15% view 
      HPV vaccine as safe in pregnancy. Many agree cost is a reason for patient refusal 
      and a deterrent from mandating the vaccine. CONCLUSION: 
      Obstetrician-gynecologists are knowledgeable of the HPV vaccine and are 
      incorporating it into practice. Financial concerns may limit widespread 
      immunization.
FAU - Leddy, Meaghan A
AU  - Leddy MA
AD  - Research Department, American College of Obstetricians and Gynecologists, 409 
      12th Street, SW, Washington, DC 20024, USA. mleddy@acog.org
FAU - Anderson, Britta L
AU  - Anderson BL
FAU - Gall, Stanley
AU  - Gall S
FAU - Schulkin, Jay
AU  - Schulkin J
LA  - eng
GR  - R60 MC 05674/PHS HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Pediatr Adolesc Gynecol
JT  - Journal of pediatric and adolescent gynecology
JID - 9610774
RN  - 0 (Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18)
RN  - 0 (Papillomavirus Vaccines)
SB  - IM
MH  - *Clinical Competence
MH  - Condylomata Acuminata/prevention & control
MH  - Data Collection
MH  - Female
MH  - Gynecology
MH  - Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
MH  - Humans
MH  - Male
MH  - Obstetrics
MH  - Papillomavirus Vaccines/*therapeutic use
MH  - *Practice Patterns, Physicians'
MH  - Uterine Cervical Neoplasms/*prevention & control
EDAT- 2009/08/04 09:00
MHDA- 2009/10/23 06:00
CRDT- 2009/08/04 09:00
PHST- 2008/07/30 00:00 [received]
PHST- 2008/09/04 00:00 [revised]
PHST- 2008/09/11 00:00 [accepted]
PHST- 2009/08/04 09:00 [entrez]
PHST- 2009/08/04 09:00 [pubmed]
PHST- 2009/10/23 06:00 [medline]
AID - S1083-3188(08)00285-4 [pii]
AID - 10.1016/j.jpag.2008.09.002 [doi]
PST - ppublish
SO  - J Pediatr Adolesc Gynecol. 2009 Aug;22(4):239-46. doi: 
      10.1016/j.jpag.2008.09.002.